Login / Signup

Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine.

Yoshifumi UwaminoTakashi YokoyamaYasunori SatoAyako ShibataToshinobu KurafujiAkiko TanabeMasayo NoguchiTomoko AraiAkemi OhnoHiromitsu YokotaHo NamkoongTomoyasu NishimuraKenjiro KosakiNaoki HasegawaMasatoshi WakuiMitsuru MurataHiromichi Matsushita
Published in: Vaccine (2023)
Longitudinal data on the immune response from the first dose to several months after the third dose of COVID-19 vaccine are limited. We analyzed the immune response in 406 Japanese healthcare workers who received at least three doses of vaccine. The geometric mean anti-receptor binding domain IgG antibody titers and antigen-stimulated T-cell interferon-gamma levels after 6 months after receiving a third dose were similar to those 8 weeks after receiving a second dose. Humoral and cellular immunity induced by the third dose was more durable than that induced by the second dose. UMIN Clinical Trials Registry ID: UMIN000043340.
Keyphrases
  • immune response
  • clinical trial
  • dendritic cells
  • sars cov
  • coronavirus disease
  • machine learning
  • binding protein
  • phase ii